These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 35165859)

  • 21. Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.
    Domschke C; Schneeweiss A; Stefanovic S; Wallwiener M; Heil J; Rom J; Sohn C; Beckhove P; Schuetz F
    Breast Care (Basel); 2016 Apr; 11(2):102-7. PubMed ID: 27239171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy.
    Baxevanis CN
    Cancer Immunol Immunother; 2019 May; 68(5):705-707. PubMed ID: 30955066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The concept of immune surveillance against tumors. The first theories.
    Ribatti D
    Oncotarget; 2017 Jan; 8(4):7175-7180. PubMed ID: 27764780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-mediated dormancy: an equilibrium with cancer.
    Teng MW; Swann JB; Koebel CM; Schreiber RD; Smyth MJ
    J Leukoc Biol; 2008 Oct; 84(4):988-93. PubMed ID: 18515327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How do tumor stem cells actively escape from host immunosurveillance?
    Qi Y; Li RM; Kong FM; Li H; Yu JP; Ren XB
    Biochem Biophys Res Commun; 2012 Apr; 420(4):699-703. PubMed ID: 22465008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution.
    Wu T; Wang G; Wang X; Wang S; Zhao X; Wu C; Ning W; Tao Z; Chen F; Liu XS
    Cancer Res; 2022 Jun; 82(12):2226-2238. PubMed ID: 35486454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
    Matsushita H; Vesely MD; Koboldt DC; Rickert CG; Uppaluri R; Magrini VJ; Arthur CD; White JM; Chen YS; Shea LK; Hundal J; Wendl MC; Demeter R; Wylie T; Allison JP; Smyth MJ; Old LJ; Mardis ER; Schreiber RD
    Nature; 2012 Feb; 482(7385):400-4. PubMed ID: 22318521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
    Liu S; Sun Q; Ren X
    J Hematol Oncol; 2023 Apr; 16(1):38. PubMed ID: 37055849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth.
    Huang Y; Lin L; Shanker A; Malhotra A; Yang L; Dikov MM; Carbone DP
    Cancer Res; 2011 Oct; 71(19):6122-31. PubMed ID: 21825014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoepigenetics: the unseen side of cancer immunoediting.
    Germenis AE; Karanikas V
    Immunol Cell Biol; 2007 Jan; 85(1):55-9. PubMed ID: 17130900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.
    Croci DO; Zacarías Fluck MF; Rico MJ; Matar P; Rabinovich GA; Scharovsky OG
    Cancer Immunol Immunother; 2007 Nov; 56(11):1687-700. PubMed ID: 17571260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NK Cells in the Tumor Microenvironment.
    Guillerey C
    Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revisiting cancer immunoediting by understanding cancer immune complexity.
    Manjili MH
    J Pathol; 2011 May; 224(1):5-9. PubMed ID: 21480229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse immunoediting: When immunity is edited by antigen.
    Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
    Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor infiltrating lymphocytes in early breast cancer.
    Pruneri G; Vingiani A; Denkert C
    Breast; 2018 Feb; 37():207-214. PubMed ID: 28363679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.
    Jones LM; Broz ML; Ranger JJ; Ozcelik J; Ahn R; Zuo D; Ursini-Siegel J; Hallett MT; Krummel M; Muller WJ
    Cancer Res; 2016 Mar; 76(6):1416-28. PubMed ID: 26719528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer immunoediting: A game theoretical approach.
    Tavakoli F; Sartakhti JS; Manshaei MH; Basanta D
    In Silico Biol; 2021; 14(1-2):1-12. PubMed ID: 33216021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of tumour-specific antigens underlies cancer immunoediting.
    DuPage M; Mazumdar C; Schmidt LM; Cheung AF; Jacks T
    Nature; 2012 Feb; 482(7385):405-9. PubMed ID: 22318517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.